Carvedilol Selectively Stimulates βArrestin2-Dependent SERCA2a Activity in Cardiomyocytes to Augment Contractility

Jennifer Maning †, Victoria L. Desimine ‡, Celina M. Pollard, Jennifer Ghandour and Anastasios Lymperopoulos *

Abstract: Heart failure (HF) carries the highest mortality in the western world and β-blockers (β-adrenergic receptor (AR) antagonists) are part of the cornerstone pharmacotherapy for post-myocardial infarction (MI) chronic HF. Cardiac β1-AR-activated βarrestin2, a G protein-coupled receptor (GPCR) adapter protein, promotes Sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA)2a SUMOylation in cardiomyocytes to Augment Contractility. Given that certain β-blockers, such as carvedilol and metoprolol, can activate βarrestins and SERCA2a in the heart, we investigated the effects of these two agents on cardiac β2AR-dependent SERCA2a SUMOylation and activity. We found that carvedilol, but not metoprolol, acutely induces βarrestin2 interaction with SERCA2a in H9c2 cardiomyocytes and in neonatal rat ventricular myocytes (NRVMs), resulting in enhanced SERCA2a SUMOylation. However, this translates into enhanced SERCA2a activity only in the presence of the β2AR-selective inverse agonist ICI 118,551 (ICI), indicating an opposing effect of carvedilol-occupied β2AR subtype on cardiac SERCA2a activity through the β2AR-selective inverse agonist ICI 118,551 (ICI). 

Keywords: β-arrestin; β1-AR; cardiac myocyte; contractility; G protein-coupled receptor; SERCA2a; signal transduction; SUMOylation

1. Introduction

Sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA)-2a is a crucial, for contractile function, calcium-handling protein expressed in the mammalian myocardium and its down-regulation is one of the molecular hallmarks of chronic heart failure (HF) [1]. SERCA2a activation is part of the signaling mechanism by which the β1-adrenergic receptors (ARs) increase cardiac contractility [2]. Agonist-bound β1-ARs however, like most G protein-coupled receptors (GPCRs), undergo functional desensitization/internalization due to the actions of βarrestin1 or -2, two universal GPCR adapter proteins, following the phosphorylation of agonist-occupied receptors by GPCR-kinases (GRKs) [3]. During receptor endocytosis, the two βarrestins initiate their own wave of G protein-independent signaling [4].
the cellular processes β-arrestins regulate is protein SUMO (small ubiquitin-like modifier)-ylation, which generally increases protein stability/levels in tissues, including the heart [5]. We have reported that cardiac β₁AR-activated β-arrestin2, but not β-arrestin1, promotes SERCA2a SUMOylation and activity, thereby directly increasing cardiac contractility [6,7]. β-arrestin2 also exerts anti-inflammatory and anti-apoptotic effects in the post-myocardial infarction (MI) heart [8].

Among the three currently US FDA-approved β-blocker drugs for human chronic HF: bisoprolol, metoprolol, and carvedilol [9,10], the latter is the only one reported to be a β-arrestin-“biased” agonist [11,12] and to upregulate SERCA2a in cardiac myocytes via gene transcriptional and anti-oxidative mechanisms [13–15]. Metoprolol (β₁AR-selective) lacks this effect [15]. Carvedilol is also known to activate Ca²⁺ signaling in CNS neurons in a β-arrestin2-dependent manner [16]. Carvedilol is pharmacologically a βAR non-subtype-selective inverse agonist, also blocking α₁ARs [17]. However, the adult human heart expresses β₁ARs;β₂ARs;α₁ARs at a ratio of 70:20:10 (in terms of total AR percentages), i.e., the β₁AR subtype is by far the most predominant cardiac AR subtype expressed [2,17]. On the other hand, carvedilol is ~7-fold more potent at human β₁AR than at β₂AR (also ~2-fold more potent at β₁AR than at α₁AR) [17]. Taken together, these findings strongly suggest that carvedilol is relatively β₁AR-selective, at least in the human heart (both non-failing and failing). In the present study, we posited that carvedilol may selectively stimulate cardiac β₁AR-dependent β-arrestin2 signaling to SERCA2a SUMOylation and activation, which would translate into enhanced contractile function.

2. Results

2.1. Carvedilol, but Not Metoprolol, Induces β-arrestin2 Interaction with Cardiac SERCA2a, Enhancing SERCA2a SUMOylation

Carvedilol is known to be a β-arrestin-“biased” agonist [11,12] and several of its well-documented beneficial effects in chronic HF have been attributed to activation of β-arrestin-dependent signaling [11,12,18]. Interestingly, carvedilol, but not metoprolol, has been reported to enhance cardiac SERCA2a levels and activity [13–15] and appears to exert minimal (if any) negative inotropy when given chronically for human HF treatment [19]. Thus, to examine whether β-arrestin2-dependent SERCA2a SUMOylation/activity plays any role in these unique, among the β-blocker drugs, effects of carvedilol, we overexpressed β-arrestin2 in H9c2 cardiomyocytes (Figure 1A) and compared carvedilol with metoprolol head-to-head in their effects on SERCA2a. Neither drug had any effect on SERCA2a SUMOylation in the absence of β-arrestin2 (i.e., in control AdGFP-transfected H9c2 cells, which express only β-arrestin1 endogenously) (Figure 1A) [7,20]. In β-arrestin2-expressing cardiomyocytes however, carvedilol acutely stimulated β-arrestin2 interaction with SERCA2a, leading to increased SUMOylation of the latter (Figure 1B,C). In contrast, metoprolol was incapable of inducing β-arrestin2 interaction with SERCA2a or of increasing SERCA2a SUMOylation (Figure 1B,C). This suggests that the mechanism by which carvedilol uniquely stimulates cardiac SERCA2a levels/activity might be the induction of β₁AR-dependent β-arrestin2 recruitment to SERCA2a and enhanced subsequent SERCA2a SUMOylation.

2.2. Carvedilol, but Not Metoprolol, Increases β-arrestin2-Dependent Cardiac SERCA2a Activity, but β₂AR Inhibits This Effect

Next, we examined whether the β-arrestin2-dependent SERCA2 SUMOylation selectively induced by carvedilol indeed results in enhanced SERCA2a activity in H9c2 cardiomyocytes, which would be expected based on the results of Figure 1. To our surprise however, carvedilol treatment did not enhance SERCA activity neither in control (AdGFP), nor in β-arrestin2-overexpressing cells (Figure 2). The same was true for metoprolol (Figure 2). Given that carvedilol, unlike metoprolol, binds both β₁- and β₂AR subtypes, we speculated that the fact it increases SUMOylation without increasing activity of SERCA2a might be due to some functional competition between carvedilol-bound β₁AR and carvedilol-occupied β₂AR signaling to SERCA2a. Indeed, that proved to be the
case, since pretreatment with the β2AR-specific inverse agonist ICI 118,551 (ICI) allowed carvedilol to acutely increase SERCA2a activity in βarrestin2-overexpressing cardiomyocytes (Figure 2). Metoprolol was again without effect. Thus, it seems that signaling by the β2AR subtype somehow prevents βarrestin2-mediated SERCA2a SUMOylation from increasing the pump’s activity in cardiomyocytes.

Figure 1. β-blockers and βarrestin2-dependent SERCA2 SUMOylation in H9c2 cardiomyocytes. (A) Immunoblotting for βarrestins in control (infected with adenovirus encoding for green fluorescent protein, AdGFP) or in H9c2 cardiomyocytes infected with adenovirus encoding for βarrestin2 (Adβarr2) to confirm βarrestin2 overexpression in the latter cells. H9c2 cardiomyocytes express only βarrestin1 (βarr1) endogenously at detectable levels (see AdGFP lanes and Refs. [7,20]). Shown is a representative blot of three independent experiments. (B,C) Immunoblotting for βarrestins, SUMO-1 and SERCA2a in SERCA2a immunoprecipitates (IPs) prepared from these cells and treated with vehicle (0.1% DMSO), 1 μM carvedilol (Carv), or 1 μM metoprolol (Meto) for 20 min. Representative blots are shown in (B) and SERCA2a SUMOylation quantitation, as measured by densitometry, is shown in (C). IB: Immunoblotting; IP: Immunoprecipitation; S-SERCA2a: SUMOylated SERCA2a; A.U.: Arbitrary (densitometric) units. Only βarrestin2 (not βarrestin1) could be detected in the SERCA2a IPs and only in Adβarr2-infected cells treated with carvedilol. *p < 0.05, vs. any other treatment/cell clone; n = 3 independent experiments.
2.3. Carvedilol, but Not Metoprolol, Stimulates Cardiomyocyte β-arrestin2-Dependent Contractility in a β2AR-Sensitive Manner

We next sought to test the impact of the increased β-arrestin2-dependent SERCA2a activity by carvedilol on cardiomyocyte contractility. Because H9c2 cardiomyoblasts do not contract, we used neonatal rat ventricular myocytes (NRVMs) instead, overexpressing β-arrestin2 via adenoviral-mediated transfection. First, we confirmed that, similarly to the H9c2 cardiomyocytes above, neither metoprolol, nor carvedilol affected SERCA2a SUMOylation in control NRVMs that express almost exclusively β-arrestin1 endogenously (Figure 3A), but carvedilol acutely stimulated β-arrestin2 interaction with SERCA2a, leading to increased SUMOylation of the latter in the β-arrestin2-expressing myocytes (Figure 3B,C). Metoprolol again did not stimulate the SERCA2a-β-arrestin2 interaction and did not affect SERCA2a SUMOylation (Figure 3B,C). We also observed that carvedilol potentiated SERCA activity only in the presence of ICI 118,551 in β-arrestin2-expressing NRVMs (Figure 3D), similarly to the H9c2 cells above (Figure 2), whereas metoprolol did not affect SERCA activity irrespective of concomitant β2AR antagonism (Figure 3D). Thus, after essentially recapitulating all our findings from H9c2 cells, we tested the effect of these β-blockers on NRVM contractility. Carvedilol alone was incapable of increasing contractility of NRVMs despite β-arrestin2 overexpression. However, upon pretreatment with ICI, it resulted in significant enhancement of contractility compared to basal conditions (0.1% DMSO, no stimulation) (Figure 3E). Metoprolol did not affect contractility regardless of concurrent β2AR blockade (Figure 3E). This finding strongly suggests that carvedilol, but not metoprolol, can increase cardiomyocyte contractility via β-arrestin2-dependent SERCA2a SUMOylation and stimulation, as long as it is prevented from binding to the β2AR, i.e., this effect of carvedilol is strictly β1AR-dependent.

**Figure 2.** β-blockers and SERCA2a activity in β-arrestin2-overexpressing H9c2 cardiomyocytes. Maximal SERCA activity in microsomes isolated from β-arrestin2-expressing (Adβarr2) or control (AdGFP) H9c2 cardiomyocytes and treated with 1 μM metoprolol (Meto), 1 μM carvedilol (Carv), or 1 μM carvedilol in the presence of 10 μM ICI 118,551 (Carv + ICI) for 30 min. *, *p < 0.05, vs. any other group; n = 3 independent measurements/transfection group/treatment.
these β-blockers on NRVM contractility. Carvedilol alone was incapable of increasing contractility of NRVMs despite β-arrestin2 overexpression. However, upon pretreatment with ICI, it resulted in significant enhancement of contractility compared to basal conditions (0.1% DMSO, no stimulation) (Figure 3E). Metoprolol did not affect contractility regardless of concurrent β2AR blockade (Figure 3E). This finding strongly suggests that carvedilol, but not metoprolol, can increase cardiomyocyte contractility via β-arrestin2-dependent SERCA2a SUMOylation and stimulation, as long as it is prevented from binding to the β2AR, i.e., this effect of carvedilol is strictly β1AR-dependent.

Figure 3. β-blockers and β-arrestin2-dependent SERCA2a function and contractility in NRVMs. (A) Immunoblotting for β-arrestins in control (AdGFP) or in NRVMs expressing β-arrestin2 (Adβarr2) to confirm β-arrestin2 transgene induction. Like H9c2 cardiomyocytes, NRVMs also appear to express only β-arrestin1 endogenously at detectable levels (see AdGFP lanes). Shown is a representative blot from three independent experiments. (B,C) Immunoblotting for β-arrestins, SUMO1 and SERCA2a in SERCA2a IPs prepared from these cells and treated with vehicle (0.1% DMSO), 1 μM carvedilol (Carv), or 1 μM metoprolol (Meto) for 20 min. Representative blots are shown in (B) and SERCA2a SUMOylation quantitation, as measured by densitometry, is shown in (C). S-SERCA2a: SUMOylated SERCA2a; A.U.: Arbitrary (densitometric) units. As in H9c2 cardiomyocytes, only β-arrestin2 could be detected in SERCA2a IPs and only in Adβarr2-infected cells treated with carvedilol. *, p < 0.05, vs. any other treatment/cell clone; n = 3 independent experiments. (D) Maximal SERCA activity potentiation in microsomes isolated from β-arrestin2-expressing (Adβarr2) or control (AdGFP) NRVMs. ICI: 10 μM ICI 118,551; Meto: 1 μM metoprolol; Carv: 1 μM carvedilol, for 30 min. *, p < 0.05, vs. any other group; n = 3 independent measurements/transfection group/treatment. (E) Cell shortening response of β-arrestin2-overexpressing NRVMs treated as in (D). *, p < 0.05, vs. any other treatment; NS: Not significant vs. basal (0.1% DMSO) at p = 0.05; n = 3 independent measurements (in triplicate)/treatment group.
2.4. Carvedilol, but Not Metoprolol, Stimulates β-arrestin2-Dependent Contractility in Human Fully Differentiated Cardiac Myocytes

To verify that the findings above hold true in bona fide human cardiac myocytes, we took advantage of the iCell® cardiomyocyte preparation available from Fujifilm Cellular Dynamics. This is essentially human cardiac (ventricular) myocytes (CMs) differentiated from human induced pluripotent stem cells (hiPSCs). After culturing the cells for two weeks, we transfected them with adenovirus encoding for β-arrestin2 (encoding also for GFP as a marker of gene transduction in a bi-cistronic manner [7]), so as to overexpress β-arrestin2 (Figure 4A). 48 h post-adenoviral infection, we applied the drugs to measure the contractile responses of the hiPSC-CMs. As shown in Figure 4B, metoprolol was without effect on cell shortening, with or without concomitant β2AR blockade with ICI. In contrast, carvedilol alone produced a weak but nevertheless significant increase in the fractional shortening of β-arrestin2-overexpressing hiPSC-CMs, a response that was further augmented by ICI pretreatment (β2AR blockade) (Figure 4B). As expected, the β1AR full agonist dobutamine elicited a far more robust (~3 times larger than carvedilol alone) contractile response (Figure 4B). Taken together, these results indicate that carvedilol can increase contractility of human fully differentiated cardiac myocytes via β1AR-activated β-arrestin2, and, unlike rat neonatal cardiomyocytes, concomitant β2AR blockade is not necessary for this pro-contractile effect of carvedilol to be manifested.

![Figure 4.](image)

Figure 4. Cell shortening response of β-arrestin2-overexpressing hiPSC-CMs. (A) Co-immunofluorescence performed on culture day 16 (48 h post-adenoviral infection) for NKX2.5 (cardiac myocyte marker, red) and for GFP (green) to confirm β-arrestin2 overexpression (the adenovirus encoding for β-arrestin2 also encoded for GFP, see Section 4.2 for details). (B) ICI: 10 μM ICI 118,551; Meto: 1 μM metoprolol; Carv: 1 μM carvedilol; Dob: 1 μM dobutamine. *, p < 0.05, vs. baseline (0.1% DMSO); #, p < 0.05, vs. Carv alone; †, p < 0.05, vs. any other treatment; NS: Not significant vs. basal (0.1% DMSO) at p = 0.05; n = 3 independent measurements in 6–8 different myocytes per drug tested.

3. Discussion

In the present study, we have uncovered a unique pharmacological action of the β-blocker carvedilol: unlike metoprolol and other β-blocker drugs commonly used in cardiovascular clinical practice, ridden with negative inotropy, carvedilol not only does not reduce cardiomyocyte contractility but actually increases it via the β1AR-β-arrestin2-SERCA2a signaling axis (Figure 5). This may translate into a direct positive inotropic effect of this β-blocker drug per se in the heart, which can further enhance (via baroreflex activation) its anti-hypertensive, vasodilatation-mediated effect, as well. Of course, this awaits confirmation in animal models in vivo and, ultimately, in patients.
Figure 5. Schematic illustration of carvedilol’s positive inotropic effect via stimulation of the β1AR-βarrestin2-SERCA2a SUMOylation axis in cardiac myocytes. See text for details. SR: Sarcoplasmic reticulum; SUMO1: Small ubiquitin-like modifier-1; ???: Effect/signaling pathway unknown.

SERCA2a has a prominent role in the myocardium regulating (enhancing) both relaxation (by removing cytosolic Ca\(^{2+}\)) and contraction (by increasing the availability of Ca\(^{2+}\) for release into the cytosol). Thus, its activation is among the most important signaling mechanisms of catecholamine-induced positive inotropy via the cardiac β1AR [1,21]. Therefore, it comes as no surprise that cardiac SERCA2a downregulation, both in terms of protein levels and pump activity, is a molecular hallmark of human HF [1]. Although initially thought to signal and function similarly to the β1AR, cardiac β2AR signaling and function are now known to be substantially different [22]. For instance, β2AR is anti-apoptotic and very minimally pro-contractile (i.e., total cellular receptor levels reduced due to reduced receptor protein synthesis), whereas the β2AR is also desensitized and dysfunctional, but its plasma membrane density is unaltered [10,24].

βarrestin1 is far more abundant than βarrestin2 in the myocardium of various species (human, murine, rat) [6,7,25,26]. Considered for a long time as functionally interchangeable, the two βarrestins are now known to exhibit remarkable functional divergence, both in heterologous cell lines in vitro and in various tissues in vivo, including in the heart [18]. More specifically, βarrestin1 exerts negative inotropy by decoupling the cardiac β1AR from G\(_{i/o}\) (inhibitory/other G) proteins [2,22,23]. β2AR also undergoes different alterations in human HF vs. the β1AR [24]. Specifically, in human HF, β1AR is desensitized and selectively downregulated (i.e., total cellular receptor levels reduced due to reduced receptor protein synthesis), whereas the β2AR is also desensitized and dysfunctional, but its plasma membrane density is unaltered [10,24].
morphic Arg389 β1 AR variant, known to be hyperfunctional and more pro-contractile in the heart than its Gly389 counterpart, interacts with βarrestin2 more efficiently and to a larger extent than the Gly389 β1 AR variant [29,30]. Importantly, βarrestin2 directly enhances cardiac contractility by (a) not affecting (desensitizing) β1 AR signaling via the Gs-cAMP pro-contractile pathway, and (b) directly binding SERCA2a and promoting its SUMOylation, a process known to acutely enhance SERCA2a protein stability and calcium-pumping activity (Figure 5) [1,6,7]. This acute effect of cardiac βarrestin2 might complement long-term stimulatory effects of this adapter protein on cardiac SERCA2a, since βarrestin2 “biased” agonism has been reported to transcriptionally upregulate cardiac SERCA2a in a mouse model of dilated cardiomyopathy [31]. Thus, βarrestin2 attenuates adverse remodeling (apoptosis and inflammation) while directly enhancing cardiac contractility (via SERCA2a potentiation) (Figure 5) [7,28].

Among the three FDA-approved β-blocker agents for chronic HF treatment, carvedilol has been postulated to be the most superior/preferred agent [9], since it appears to exert favorable effects on cardiac contractility [19]. Restoration of adrenal GRK2-α2 AR-catecholamine secretion axis and suppression of norepinephrine release from cardiac sympathetic nerve terminals contribute to the beneficial effects of β-blockers in HF [32,33]. Carvedilol has several unique, among the β-blocker class, properties: significant vasodilation, as α1 AR-blocker, which minimizes (via the baroreceptor reflex mechanism) the negative effect of cardiac β AR blockade on cardiac output and may also inhibit the cardiotoxic maladaptive effects of cardiac α1 ARs (maladaptive hypertrophy) [2,17,34–36]; potent anti-oxidant, anti-endothelin, and anti-proliferative agent [9,37,38]; and, unlike all other β-blockers (including metoprolol) that upregulate β1 AR in the failing human heart, carvedilol does not reverse β1 AR downregulation in the failing heart despite exerting complete β AR blockade [17,35,39]. This is probably due to the fact that carvedilol has also unique sympatholytic properties, keeping norepinephrine levels in HF patients at bay [35]. This sympatholysis, coupled with its potent inverse agonism at cardiac β ARs (especially at the β1 AR), and with its significant affinity for all three types of cardiac ARs (β1 AR, β2 AR, α1 AR), culminates in a powerful, almost complete adrenergic blockade by carvedilol in human HF [17,35].

Given that the negative inotropy exerted by β-blockers limits exercise capacity and reduces quality of life of HF patients, the β-blocker agent(s) resulting in the smallest reduction in cardiac contractility are preferred for HF with reduced ejection fraction (HFrEF) treatment. Carvedilol has been suggested to lack a direct negative effect on cardiac contractility and may directly increase it in human HF [19], possibly because it increases SERCA2a levels and activity [13–15]. Additionally, carvedilol stimulates intracellular Ca2+ signaling via βarrestin2 (but not βarrestin1) in native central nervous system neurons, an effect that might also be mediated by SERCA upregulation [16]. Our present study focused on comparing the pro-contractile effects of carvedilol vs. metoprolol, since only these two agents, out of the three currently approved for chronic HF (i.e., not bisoprolol), are known to activate βarrestin signaling [11,12]. Our findings strongly suggest that carvedilol, but not metoprolol, enhances SERCA2a SUMOylation and activity via βarrestin2 in cardiac myocytes, resulting in direct augmentation of cardiac contractility (Figure 5). Metoprolol lacks this effect, perhaps because it stimulates βarrestin1 (rather than βarrestin2) binding to the cardiac β1 AR and βarrestin1 cannot stimulate SERCA2a SUMOylation or activity [7]. Thus, carvedilol, either alone or combined with cardiac-specific βarrestin2 gene therapy, can provide relief for acute HF decompensation episodes during the long-term treatment of chronic human HF. Importantly, given that βarrestin2 inhibits apoptosis and inflammation in the post-MI heart (Figure 5) [7,8], carvedilol’s putative positive inotropy should be safe for the myocardium. Our findings on carvedilol’s pro-contractile effects in cardiac myocytes are consistent with a recent study reporting that this β-blocker uniquely enhances skeletal muscle contractility, as well [40]. Although this effect of carvedilol was attributed to βarrestin1, rather than βarrestin2, and to β2 AR signaling, instead of β1 AR, the specific underlying signaling mechanisms were not investigated [40]. In addition, this study was
done exclusively in transgenic mice in vivo, in which skeletal muscle $\beta_2$AR activation by endogenous catecholamines could very well have skewed the observed effects of carvedilol on contractility.

There are some obvious caveats associated with our present findings. First, carvedilol requires $\beta$arrestin2 to stimulate contractility, which is normally minimally expressed in the adult heart [6,25,26]. Moreover, carvedilol causes robust sympatholysis and does not reverse cardiac $\beta_1$AR downregulation in human HF. Taken together, these observations suggest that the weak positive inotropic effect of carvedilol manifested in cardiomyocytes in vitro may be masked or significantly blunted/offset in human HF in vivo. Indeed, carvedilol was found ineffective at stimulating $\beta$arrestin-dependent contractility in isolated primary murine cardiomyocytes [26], probably because these myocytes, like their human counterparts, exhibit minimal $\beta$arrestin2 protein expression (contrary to the very robust $\beta$arrestin1 expression) [7,26]. Nevertheless, $\beta$arrestin2 levels may change (increase) in failing human hearts, in an effort to compensate for the functional decline; thus, carvedilol’s positive inotropy via $\beta$arrestin2 may become manifested in HF patients. Indeed, a recent study hinted at $\beta$arrestin2 upregulation in failing rat hearts [41]. Another pitfall emerging from our present work is the antagonism the cardiac $\beta_2$AR subtype seems to exert on carvedilol’s effects on SERCA2a. The underlying mechanism(s) for this is presently unknown but one possible explanation would be that perhaps the carvedilol-occupied $\beta_2$AR subtype favors $\beta$arrestin1 over $\beta$arrestin2 activation in the heart. $\beta$arrestin1 not only does not promote SERCA activity, like $\beta$arrestin2 does, but also, indirectly, decreases it by desensitizing $\beta$AR signaling towards cAMP-protein kinase A (PKA)-dependent SERCA2a activation [7]. Another potential explanation for the opposite effects of $\beta_2$AR (vs. $\beta_1$AR) on carvedilol-induced SERCA2a SUMOylation and activation is that the $\beta_2$AR, unlike the $\beta_1$AR, can also couple to Gi/o proteins [23]. Gi/o protein signaling dampens cAMP levels in the heart, thereby reducing SERCA2a activity and contractility, which would work against carvedilol’s actions. Nevertheless, in the adult human cardiomyocyte, wherein the $\beta_1$AR subtype is far more abundant than the $\beta_2$AR subtype [17], this negative effect of the $\beta_2$AR on carvedilol’s pro-contractile effects via SERCA2a might be negligible. Our data in hIPSC-CMs (Figure 4), in which carvedilol was capable of increasing contractility without concomitant $\beta_2$AR blockade, strongly hint at this possibility. Of note, H9c2 cardiomyoblasts and neonatal cardiomyocytes express much higher $\beta_2$AR densities than adult cardiomyocytes [7,42,43], which could explain why $\beta_2$AR blockade is necessary to unmask carvedilol’s effects on SERCA2a and contractility in H9c2 cells and in NRVMs but not necessary at all in hIPSC-CMs. Finally, carvedilol’s pro-contractile effect is quite weak, especially when compared to the robust cardiomyocyte response to standard cardiac $\beta_1$AR agonists like dobutamine (Figure 4). This is totally expected however, since carvedilol, unlike dobutamine, cannot stimulate the Gs protein/cAMP signaling pathway, which robustly increases cardiomyocyte contractility [2,21].

Our present study has two major limitations: (a) Although we used physiologically relevant cells (cardiomyoblasts, neonatal cardiomyocytes, and stem cell-derived differentiated cardiomyocytes), these cells were not, nonetheless, primary bona fide adult cardiomyocytes and were studied exclusively in vitro; and (b) Our findings obviously require confirmation in vivo models and settings. Nevertheless, given that the cell models we employed were differentiated cardiac myocytes, including, importantly, human cardiomyocytes, our present findings are quite likely to hold true in adult human primary cardiomyocytes in vivo, as well.

In conclusion, carvedilol, uniquely among $\beta$-blockers, increases cardiomyocyte contractility via $\beta_1$AR-activated, $\beta$arrestin2-dependent SERCA2a SUMOylation and potentiation. Thus, contrary to the conventional wisdom that all $\beta$-blockers are negative inotropes, which complicates their use and limits their dosages in human chronic HF therapy, carvedilol may have direct positive inotropic actions in the human failing myocardium. This would give carvedilol the special advantage of being suitable for use in chronic human HFrEF complicated by frequent acute decompensated HF episodes.
4. Materials and Methods

4.1. Materials

All drugs and chemicals were from Sigma-Aldrich (St. Louis, MO, USA).

4.2. Cell Culture and Transfections

The H9c2 rat cardiomyoblast cell line was purchased from American Type Culture Collection (Manassas, VA, USA) and cultured as previously described [7]. NRVMs were purchased from Lonza (Cat. #R-CM-561; Lonza Group Ltd., Basel, Switzerland) and plated and cultured according to the supplier’s manual. hISPC-CMs (iCell® cardiomyocytes) were purchased from Fujifilm Cellular Dynamics, Inc. (Cat. #R1105; FCDI, Madison, WI, USA) and plated and cultured in the supplier’s provided culture medium according to their instructions. Recombinant adenoviruses encoding for green fluorescent protein (AdGFP) and for rat wild type full-length βarrestin2 (Adβarr2, also encoding for GFP via a bi-cistronic construct) were constructed as described previously [7,44]. Briefly, transgenes were cloned into shuttle vector pAdTrack-CMV, which harbors a CMV-driven GFP, to form the viral constructs by using standard cloning protocols. The resultant adenoviruses were purified using two sequential rounds of CsCl density gradient ultracentrifugation, as described previously [44]. To verify the identity of hIPSC-CMs as cardiomyocytes, immunofluorescence with an antibody against human NKX2.5 (cardiomyocyte marker) (Cat. #SAB2501264; Sigma Aldrich) was performed as described previously [44]. To confirm overexpression of βarrestin2 in hIPSC-CMs, GFP fluorescence (green) was visualized under a fluorescence microscope.

4.3. Immunoprecipitation/Western Blotting for SERCA SUMOylation Determination

Protein concentration was determined and equal amounts of protein per sample were used for immunoprecipitation (IP) or Western blotting. SERCA2a was immunoprecipitated by overnight incubation of extracts with an anti-SERCA2 antibody (Cat. #4388; Cell Signaling Technology, Danvers, MA, USA), attached to Protein A/G-Sepharose beads (Sigma-Aldrich). The IPs were then subjected to immunoblotting for βarrestins with an anti-βarrestin1/2 antibody (Cat. #sc-28869; Santa Cruz Biotechnology, Santa Cruz, CA, USA), for SUMO-1 (Cat. #4930; Cell Signaling Technology), and for SERCA2, to confirm IP of equal amounts of endogenous SERCA2a among the various treatments. Immunoblots were revealed by enhanced chemiluminescence (ECL, Life Technologies, Grand Island, NY, USA) and visualized in the FluorChem E Digital Darkroom (Protein Simple, San Jose, CA, USA), as described previously [7]. Densitometry was performed with the AlphaView software (Protein Simple) in the linear range of signal detection (on non-saturated bands).

4.4. SERCA Activity

Maximal SERCA activity was measured as described [7,15,45]. Briefly, lysates were prepared and assayed in 10 mM Tris, pH 7.5, 100 mM KCl, 5 mM MgCl2, 5 mM Na2ATP, 0.1 mM CaCl2, 0.2 mM NADH, 1.5 mM trisodium phosphoenolpyruvate, 15 units/mL pyruvate kinase, and 36 units/mL lactate dehydrogenase. Total ATPase activity was assayed by monitoring the rate of loss of A340 after addition of the membrane preparation to a thermostatically controlled (37 °C) cuvette in a spectrophotometer. Background ATPase activity was determined in the absence of ATP. Ca2+-independent ATPase activity was assayed in the presence of 10 mM EGTA, instead of Ca2+, and subtracted from the total ATPase activity to derive the Ca2+-dependent ATPase (SERCA) activity. SERCA activity was calculated as nmol of inorganic phosphate (P) produced per min per mg of protein.

4.5. Cell Shortening Measurements

NRVMs or hIPSC-CMs were plated on laminin-coated glass coverslips, in a buffer with serial Ca2+ concentration titrations. The myocytes were then placed in MEM (Sigma-Aldrich) containing 1.2 mM Ca2+, 2.5% (v/v) FBS, and 1% penicillin/streptomycin. The pH was adjusted to 7.0 in 5% CO2 by the addition of NaHCO3. After 1 h at 5% CO2 and 37 °C,
medium was replaced with serum-free MEM containing 0.1 mg/mL bovine serum albumin (BSA). Myocytes attached to coverslips were bathed in 700 µL of air/37°C-equilibrated, 20 mM HEPES (pH 7.4)-buffered Medium 199 (Sigma-Aldrich), containing 1.8 mM calcium and 100 nM N106 [7] to acutely stimulate SERCA2a SUMOylation, and used within 2 h of plating. Contractility (cell shortening) was measured at a pacing frequency of 2 Hz immediately upon drug (or DMSO) addition into the medium via a digital videocamera connected to the microscope, as described [46,47]. Briefly, to calculate the drug-induced % shortening, the baseline (without drug) length change was subtracted from the drug-induced one for each drug/agent, and then plotted as % change (increase in cell length shortening) over no drug stimulation. For example: an average Δlength of ~5 µm was observed both with and without Meto, indicating 0% contractility increase, but Dob addition resulted in average Δlength of ~7.5 µm from a baseline average Δlength of ~5 µm (without Dob), i.e., ~50% contractility increase on average. The measurements were done for 6–8 different myocytes per drug tested and the whole series of drugs was tested three independent times (i.e., after three independent myocyte platings). The operator was blinded as to the identity of the drug/agent added each time.

4.6. Statistical Analysis

Data are generally expressed as mean ± SEM. Unpaired 2-tailed Student’s t test and one- or two-way ANOVA with Bonferroni test were generally performed for statistical comparisons, unless otherwise indicated. For most 3-group statistical comparisons, Dunnett’s test using SAS version 9 software (SAS Institute Inc., Cary, NC, USA) was used, as well. For all tests, a p value of <0.05 was generally considered to be significant.

Author Contributions: J.M., V.L.D., C.M.P. and J.G. performed research. A.L. supervised the project, performed data analysis, provided funding for the study, and wrote the manuscript with input from J.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded in part by an American Heart Association Scientist Development Grant (AHA 09SDG2010138, National Center) and an American Foundation for Pharmaceutical Education (AFPE) “Gateway to Research” award (both to A.L.).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All source data files are available upon request to the correspondence author.

Acknowledgments: We thank the lab of Gaofeng Wang (University of Miami, Miami, FL, USA) for excellent technical assistance.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Kho, C.; Lee, A.; Hajjar, R.J. Altered sarcoplasmic reticulum calcium cycling–targets for heart failure therapy. Nat. Rev. Cardiol. 2012, 9, 717–733. [CrossRef] [PubMed]
2. Lymperopoulos, A.; Rengo, G.; Koch, W.J. Adrenergic nervous system in heart failure: Pathophysiology and therapy. Circ. Res. 2013, 113, 739–753. [CrossRef] [PubMed]
3. Gurevich, V.V.; Gurevich, E.V. GPCR Signaling Regulation: The Role of GRKs and Arrestins. Front. Pharmacol. 2019, 10, 125. [CrossRef] [PubMed]
4. Luttrell, L.M.; Gesty-Palmer, D. Beyond desensitization: Physiological relevance of arrestin-dependent signaling. Pharmacol. Rev. 2010, 62, 305–330. [CrossRef] [PubMed]
5. Wyatt, D.; Malik, R.; Vesecky, A.C.; Marchese, A. Small ubiquitin-like modifier modification of arrestin-3 regulates receptor trafficking. J. Biol. Chem. 2011, 286, 3884–3893. [CrossRef]
6. McCrink, K.A.; Maning, J.; Yu, A.; Jafferjee, M.; Marrero, C.; Brill, A.; Bathgate-Siryk, A.; Dabul, S.; Koch, W.J.; Lymperopoulos, A. Cardiac βarrestin2 Improves Contractility and Adverse Remodeling in Heart Failure, But Is Underexpressed in Humans. J. Am. Coll. Cardiol. 2017, 70, 2948–2949. [CrossRef]
7. McCrink, K.A.; Maning, J.; Vu, A.; Jafferjee, M.; Marrero, C.; Brill, A.; Bathgate-Siryk, A.; Dabul, S.; Koch, W.J.; Lymeropoulos, A. β-Arrestin2 Improves Post-Myocardial Infarction Heart Failure via Sarco(endo)plasmic Reticulum Ca²⁺-ATPase-Dependent Positive Inotropy in Cardiomyocytes. Hypertension 2017, 70, 972–981. [CrossRef]

8. Watari, K.; Nakaya, M.; Nishida, M.; Kim, K.M.; Kurose, H. β-arrestin2 in infiltrated macrophages inhibits excessive inflammation after myocardial infarction. PLoS ONE 2013, 8, e66351. [CrossRef]

9. Remme, W.J. Which beta-blocker is most effective in heart failure? Cardiovasc. Drugs Ther. 2010, 24, 351–358. [CrossRef]

10. Bristow, M. Antiadrenergic therapy of chronic heart failure: Surprises and new opportunities. Circulation 2003, 107, 1100–1102. [CrossRef]

11. Wang, J.; Pani, B.; Gokhan, I.; Xiong, X.; Kahsai, A.W.; Jiang, H.; Ahn, S.; Lefkowitz, R.J.; Rockman, H.A. β-Arrestin-Biased Allosteric Modulator Potentiates Carvedilol-Stimulated β Adrenergic Receptor Cardioprotection. Mol. Pharmacol. 2021, 100, 568–579. [CrossRef] [PubMed]

12. Wang, J.; Gareri, C.; Rockman, H.A. G-Protein-Coupled Receptors in Heart Disease. Circ. Res. 2018, 123, 716–735. [CrossRef] [PubMed]

13. Sun, Y.L.; Hu, S.J.; Wang, L.H.; Hu, Y.; Zhou, J.Y. Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. Chest 2005, 128, 1812–1821. [CrossRef] [PubMed]

14. Sun, Y.L.; Hu, S.J.; Wang, L.H.; Hu, Y.; Zhou, J.Y. Comparison of low and high doses of carvedilol on restoration of cardiac function and calcium-handling proteins in rat failing heart. Clin. Exp. Pharmacol. Physiol. 2005, 32, 553–560. [CrossRef]

15. Koitabashi, N.; Arai, M.; Tomaru, K.; Takizawa, T.; Watanabe, A.; Niwano, K.; Yokoyama, T.; Wuytack, F.; Periasamy, M.; Nagai, R.; et al. Carvedilol effectively blocks oxidative stress-mediated downregulation of sarcoplasmic reticulum Ca²⁺-ATPase 2 gene transcription through modification of Sp1 binding. Biochem. Biophys. Res. Commun. 2005, 328, 116–124. [CrossRef]

16. Tzingounis, A.V.; von Zastrow, M.; Yudowski, G.A. [beta]-blocker drugs mediate calcium signaling in native central nervous system neurons by [beta]-arrestin-biased agonism. Proc. Natl. Acad. Sci. USA 2010, 107, 21028–21033. [CrossRef]

17. Yoshikawa, T.; Port, J.D.; Asano, K.; Chidiak, P.; Bouvier, M.; Dutcher, D.; Roden, R.L.; Minobe, W.; Tremmel, K.D.; Bristow, M. Cardiac adrenergic receptor effects of carvedilol. Eur. Heart J. 1996, 17 (Suppl. B), 8–16. [CrossRef] [PubMed]

18. Srivastava, A.; Gupta, B.; Gupta, C.; Shukla, A.K. Emerging Functional Divergence of β-Arrestin Isoforms in GPCR Function. Trends Endocrinol. Metab. 2015, 26, 628–642. [CrossRef]

19. Bozkurt, B.; Bolos, M.; Deswal, A.; Ather, S.; Chan, W.; Mann, D.L.; Carabello, B. New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients—A matter of time for contractility. J. Card. Fail. 2012, 18, 183–193. [CrossRef]

20. Zhu, W.; Tilley, D.G.; Myers, V.D.; Coleman, R.C.; Feldman, A.M. Arginine vasopressin enhances cell survival via a G protein-coupled receptor kinase 2/β-arrestin1/extracellular-regulated kinase 1/2-dependent pathway in H9c2 cells. Mol. Pharmacol. 2013, 84, 227–235. [CrossRef]

21. Bers, D.M. Calcium cycling and signaling in cardiac myocytes. Annu. Rev. Physiol. 2008, 70, 23–49. [CrossRef] [PubMed]

22. Capote, L.A.; Perez, R.M.; Lymeropoulos, A. GPCR signaling and cardiac function. Eur. J. Pharmacol. 2015, 763 Pt B, 143–148. [CrossRef]

23. Daaka, Y.; Luttrell, L.M.; Lefkowitz, R.J. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997, 390, 88–91. [CrossRef]

24. Bristow, M.R.; Ginsburg, R.; Umans, V.; Fowler, M.; Minobe, W.; Rasmussen, R.; Zera, P.; Menlove, R.; Shah, P.; Jamieson, S.; et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ. Res. 1986, 59, 297–309. [CrossRef] [PubMed]

25. Ungurer, M.; Parruti, G.; Böhm, M.; Puzych, M.; DeBlasi, A.; Erdmann, E.; Lohse, M.J. Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. Circ. Res. 1994, 74, 206–213. [CrossRef] [PubMed]

26. Carr, R.; Schilling, J.; Song, J.; Carter, R.L.; Du, Y.; Yoo, S.M.; Traynham, C.J.; Koch, W.J.; Cheung, J.Y.; Tilley, D.G.; et al. β-arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction. Proc. Natl. Acad. Sci. USA 2016, 113, E4107–E4116. [CrossRef]

27. Conner, D.A.; Mathier, M.A.; Mortensen, R.M.; Christe, M.; Vatner, S.F.; Seidman, C.E.; Seidman, J.G. beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation. Circ. Res. 1997, 81, 1021–1026. [CrossRef]

28. Bathgate-Siryk, A.; Dabul, S.; Pandya, K.; Walklett, K.; Rengo, G.; Cannavo, A.; De Lucia, C.; Liccardo, D.; Gao, E.; Leoso, D.; et al. Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neuroendocrine mechanisms. Hypertension 2014, 63, 404–412. [CrossRef]

29. Ahles, A.; Rodewald, F.; Rochais, F.; Bünemann, M.; Engelhardt, S. Interhelical interaction and receptor phosphorylation regulate the activation kinetics of different human β1-adrenoceptor variants. J. Biol. Chem. 2015, 290, 1760–1769. [CrossRef]

30. McCrink, K.A.; Brill, A.; Jafferjee, M.; Valero, T.R.; Marrero, C.; Rodriguez, M.M.; Hale, G.M.; Lymeropoulos, A. β3-adrenoceptor Arg389Gly polymorphism confers differential β-arrestin-binding tropism in cardiac myocytes. Pharmacogenomics 2016, 17, 1611–1620. [CrossRef]

31. Ryba, D.M.; Li, J.; Cowan, C.L.; Russell, B.; Wolska, B.M.; Solaro, R.J. Long-Term Biased β-Arrestin Signaling Improves Cardiac Structure and Function in Dilated Cardiomyopathy. Circulation 2017, 135, 1056–1070. [CrossRef] [PubMed]
32. Lymperopoulos, A.; Rengo, G.; Funakoshi, H.; Eckhart, A.D.; Koch, W.J. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. *Nat. Med.* 2007, 13, 315–323. [CrossRef] [PubMed]

33. Rengo, G.; Lymperopoulos, A.; Zincarelli, G.; Femminella, G.; Liccardo, D.; Pagano, G.; de Lucia, C.; Cannavo, A.; Gargiulo, P.; Ferrara, N.; et al. Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2) -adrenoceptor-catecholamine production axis in heart failure. *Br. J. Pharmacol.* 2012, 166, 2430–2440. [CrossRef]

34. MacGregor, J.F.; Wachter, S.B.; Munger, M.; Stoddard, G.; Bristow, M.R.; Gilbert, E.M. Carvedilol produces sustained long-term benefits: Follow-up at 12 years. *Congest. Heart Fail.* 2009, 15, 5–8. [CrossRef] [PubMed]

35. Gilbert, E.M.; Abraham, W.T.; Olsen, S.; Hattler, B.; White, M.; Mealy, P.; Larrabee, P.; Bristow, M.R. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. *Circulation* 1996, 94, 2817–2825. [CrossRef] [PubMed]

36. Quaife, R.A.; Gilbert, E.M.; Christian, P.E.; Datz, F.L.; Mealey, P.C.; Volkman, K.; Olsen, S.L.; Bristow, M.R. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. *Am. J. Cardiol.* 1996, 78, 779–784. [CrossRef]

37. Flesch, M.; Maack, C.; Cremers, B.; Bäumer, A.T.; Südkamp, M.; Böhm, M. Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. *Circulation* 1999, 100, 346–353. [CrossRef]

38. Gillis, R.D.; Botteri, E.; Chang, A.; Ziegler, A.I.; Chung, N.C.; Pon, C.K.; Shackleford, D.M.; Andreassen, B.K.; Halls, M.L.; Baker, J.G.; et al. Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients. *Eur. J. Cancer* 2021, 147, 106–116. [CrossRef]

39. laccarino, G.; Tomhave, E.D.; Lefkowitz, R.J.; Koch, W.J. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. *Circulation* 1998, 98, 1783–1789. [CrossRef]

40. Kim, J.; Grotegut, C.A.; Wisler, J.W.; Mao, L.; Rosenberg, P.B.; Rockman, H.A.; Lefkowitz, R.J. The β-arrestin-biased β-adrenergic receptor blocker carvedilol enhances skeletal muscle contractility. *Proc. Natl. Acad. Sci. USA* 2020, 117, 12435–12443. [CrossRef]

41. Philip, J.L.; Xu, X.; Han, M.; Akhter, S.A.; Razzaque, M.A. Regulation of cardiac fibroblast-mediated maladaptive ventricular remodeling by β-arrestins. *PLoS ONE* 2019, 14, e0219011. [CrossRef] [PubMed]

42. Yano, N.; Suzuki, D.; Endoh, M.; Tseng, A.; Stabila, J.P.; McGonnigal, B.G.; Zhao, T.C.; Padbury, J.F.; Tseng, Y.T. Beta-adrenergic receptor mediated protection against doxorubicin-induced apoptosis in cardiomyocytes: The impact of high ambient glucose. *Endocrinology* 2008, 149, 6449–6461. [CrossRef] [PubMed]

43. Kuznetsov, V.; Pak, E.; Robinson, R.B.; Steinberg, S.F. Beta 2-adrenergic receptor actions in neonatal and adult rat ventricular myocytes. *Circ. Res.* 1995, 76, 40–52. [CrossRef]

44. Lymperopoulos, A.; Rengo, G.; Zincarelli, C.; Kim, J.; Soltys, S.; Koch, W.J. An adrenal β-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. *Proc. Natl. Acad. Sci. USA* 2009, 106, 5825–5830. [CrossRef] [PubMed]

45. Kho, C.; Lee, A.; Jeong, D.; Oh, J.G.; Chaanine, A.H.; Kizana, E.; Park, W.J.; Hajjar, R.J. SUMO1-dependent modulation of SERCA2a in heart failure. *Nature* 2011, 477, 601–605. [CrossRef]

46. Zhang, X.Q.; Song, J.; Rothblum, L.I.; Lun, M.; Wang, X.; Ding, F.; Dunn, J.; Lytton, J.; McDermott, P.J.; Cheung, J.Y. Overexpression of Na+/Ca2+ exchanger alters contractility and SR Ca2+ content in adult rat myocytes. *Am. J. Physiol. Heart Circ. Physiol.* 2001, 281, H2079–H2088. [CrossRef] [PubMed]

47. Song, J.; Zhang, X.Q.; Wang, J.; Cheskus, E.; Chan, T.O.; Feldman, A.M.; Tucker, A.L.; Cheung, J.Y. Regulation of cardiac myocyte contractility by phospholemman: Na+/Ca2+ exchange versus Na+ -K+ -ATPase. *Am. J. Physiol. Heart Circ. Physiol.* 2008, 295, H1615–H1625. [CrossRef]